People · Operator
Named in public records as an officer, director or promoter · active 2013–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Boreal Genomics Inc. | — | Biotechnology | Series B | $24.5M | $714.4M | 2013 |
DAVID BROEMELING at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DAVID BROEMELING on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Crandell | 1 | 11 |
| Nicholas Naclerio | 1 | 5 |
| Thomas Willis | 1 | 3 |
| Caley Castelein | 1 | 2 |
| NITIN SOOD | 1 | 1 |
| ANDREA MARZIALI | 1 | 1 |
| David Broemling | 1 | 1 |
| Keith Crandall | 1 | 1 |
| Andre Marziali | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.